Your browser doesn't support javascript.
loading
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.
Amanat, Fatima; White, Kris M; Miorin, Lisa; Strohmeier, Shirin; McMahon, Meagan; Meade, Philip; Liu, Wen-Chun; Albrecht, Randy A; Simon, Viviana; Martinez-Sobrido, Luis; Moran, Thomas; García-Sastre, Adolfo; Krammer, Florian.
Afiliación
  • Amanat F; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • White KM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Miorin L; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Strohmeier S; Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • McMahon M; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Meade P; Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Liu WC; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Albrecht RA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Simon V; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Martinez-Sobrido L; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Moran T; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • García-Sastre A; Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
Curr Protoc Microbiol ; 58(1): e108, 2020 09.
Article en En | MEDLINE | ID: mdl-32585083
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2: Screening of anti-SARS-CoV-2 compounds in vitro Support Protocol: SARS-CoV-2 propagation.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pruebas de Neutralización / Evaluación Preclínica de Medicamentos / Betacoronavirus / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Animals / Humans Idioma: En Revista: Curr Protoc Microbiol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pruebas de Neutralización / Evaluación Preclínica de Medicamentos / Betacoronavirus / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Animals / Humans Idioma: En Revista: Curr Protoc Microbiol Año: 2020 Tipo del documento: Article